ExpreS2ion Biotech Holding Future Growth
Future criteria checks 0/6
ExpreS2ion Biotech Holding's revenue is forecast to decline at 1.7% per annum while its annual earnings are expected to grow at 45.1% per year. EPS is expected to grow by 50.9% per annum.
Key information
45.1%
Earnings growth rate
50.9%
EPS growth rate
| Biotechs earnings growth | 38.7% |
| Revenue growth rate | -1.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 03 Apr 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 9 | -40 | N/A | N/A | 1 |
| 12/31/2024 | 9 | -50 | N/A | N/A | 1 |
| 12/31/2023 | 9 | -96 | -103 | -101 | N/A |
| 9/30/2023 | 8 | -125 | -129 | -127 | N/A |
| 6/30/2023 | 7 | -136 | -139 | -136 | N/A |
| 3/31/2023 | 7 | -131 | -126 | -124 | N/A |
| 12/31/2022 | 6 | -119 | -100 | -100 | N/A |
| 9/30/2022 | 9 | -84 | -65 | -64 | N/A |
| 6/30/2022 | 11 | -63 | -48 | -48 | N/A |
| 3/31/2022 | 14 | -47 | -36 | -35 | N/A |
| 12/31/2021 | 14 | -44 | -46 | -46 | N/A |
| 9/30/2021 | 15 | -47 | -52 | -51 | N/A |
| 6/30/2021 | 15 | -42 | -50 | -49 | N/A |
| 3/31/2021 | 14 | -38 | -36 | -36 | N/A |
| 12/31/2020 | 15 | -32 | -19 | -18 | N/A |
| 9/30/2020 | 14 | -21 | -9 | -8 | N/A |
| 6/30/2020 | 14 | -19 | -6 | -6 | N/A |
| 3/31/2020 | 14 | -18 | -16 | -15 | N/A |
| 12/31/2019 | 14 | -17 | -12 | -11 | N/A |
| 9/30/2019 | 12 | -16 | -15 | -14 | N/A |
| 6/30/2019 | 11 | -18 | -15 | -14 | N/A |
| 3/31/2019 | 9 | -18 | -15 | -14 | N/A |
| 12/31/2018 | 9 | -17 | -14 | -13 | N/A |
| 9/30/2018 | 9 | -14 | -13 | -12 | N/A |
| 6/30/2018 | 9 | -13 | -12 | -11 | N/A |
| 3/31/2018 | 8 | -12 | -7 | -7 | N/A |
| 12/31/2017 | 10 | -10 | -9 | -9 | N/A |
| 9/30/2017 | 13 | -15 | N/A | -12 | N/A |
| 12/31/2016 | 7 | -13 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXPRS2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EXPRS2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EXPRS2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EXPRS2's revenue is expected to decline over the next 3 years (-1.7% per year).
High Growth Revenue: EXPRS2's revenue is forecast to decline over the next 3 years (-1.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EXPRS2's Return on Equity is forecast to be high in 3 years time